PCSK9 and atherosclerosis: Two guidelines (42, 45) addressed high ASCVD risk populations (15–20% and > 20% over 5 years), recommending with low inconsistency the consideration of additional lipid-lowering agents like ezetimibe and PCSK9 inhibitors based on individual risk levels.